Table 3.
Detailed analysis of OARs and summary of the late toxicity
| Patient | Prior RT field | High-dose overlap | Most concerned OARs at Re-RT | Prior RT EQD2 (α/β = 3) |
Re-RT EQD2 (α/β = 3) |
Total EQD2 (α/β = 3) |
Bev use |
Late toxicity (CTCAE Ver.5.0) |
Time to toxicity (months) |
|---|---|---|---|---|---|---|---|---|---|
| #1 | WP | Complete | Bladder Small bowel Urethra |
43.2 43.2 43.2 |
26.9 11.9 21.2 |
70.1 55.1 64.4 |
Yes | Urinary frequency (Gr 1) lower leg edema (Gr 2) |
19 23 |
| #2 | SP | Complete | Small bowel | 27 | 54.1 | 81.1 | Yes | ||
| #3 | WP | Complete | Small bowel | 40 | 14.7 | 54.7 | Yes | ||
| #4 | Anastomosis presacrum |
Complete | Bladder Small bowel |
79.3 37.4 |
45.2 33.3 |
124.5 70.7 |
Yes | Dysuria (Gr 1) | 7 |
| #5 | HP | Partial | Bladder Sigmoid/rectum |
50 50 |
68.3 58.6 |
118.3 108.6 |
No | ||
| #6 | WP | Complete | Bladder Small bowel |
56 56 |
58.8 45.7 |
114.8 101.7 |
Yes | ||
| #7 | WP | Complete | Bladder Sigmoid/rectum Uterus |
60 60 60 |
74.4 83.4 82.2 |
134.4 143.4 142.2 |
Yes | ||
| #8 | Presacrum | Partial | Bladder Small bowel Sigmoid/rectum |
4.2 0 79.5 |
63.5 66.8 8.4 |
67.7 66.8 87.9 |
No | Colonic hemorrhage (colostomy) (Gr 4) | 15 |
| #9 | WP | Complete | Bladder Sigmoid/rectum |
50 50 |
52.1 57.1 |
102.1 107.1 |
Yes | ||
| #10 | HP | Complete | Sigmoid Pelvic bone |
48.4 48.4 |
23 68.5 |
71.4 116.9 |
No |
Bev = bevacizumab; CTCAE = Common Terminology Criteria for Adverse Events; EQD2 = equivalent dose in 2 Gy fraction; HP = hemi pelvis; Re-RT = reirradiation; RT = radiation therapy; SP = small pelvis; WP = whole pelvis.